Table 2.
The outcomes in patients with and without tranexamic acid
| Outcomes | Total (n = 8042) |
TXA (n = 3664) |
no TXA (n = 4378) |
p-value | |||
|---|---|---|---|---|---|---|---|
| PJI (n, %) | 133 | (1.7) | 39 | (1.1) | 94 | (2.1) | < 0.001 |
| Transfusion (n, %) | 1519 | (18.9) | 527 | (14.4) | 992 | (22.7) | < 0.001 |
| Length of stay, day (mean ± SD) | 6.1 | ± 2.2 | 5.6 | ± 1.6 | 6.5 | ± 2.5 | < 0.001 |
| DVT/PE (n, %) | 62 | (0.8) | 31 | (0.8) | 31 | (0.7) | 0.481 |
| 90-day re-admission (n, %) | 100 | (1.2) | 50 | (1.4) | 50 | (1.1) | 0.370 |
TXA, tranexamic acid; PJI, periprosthetic joint infection; DVT, deep vein thrombosis; PE, pulmonary embolism; SD; standard deviation